鬆景科技(01079.HK)盈警:預計年度淨虧損不少於1450萬港元
格隆匯9月19日丨鬆景科技(01079.HK)公告,公司董事會謹此知會公司股東及潛在投資者,根據公司管理層目前可獲得資料及集團最近期未經審覈綜合管理賬目之初步審閱及評估,集團預期於截至2025年6月30日止年度錄得未經審覈除稅後綜合淨虧損不少於約1450萬港元,而截至2024年6月30日止年度則錄得經審覈除稅後綜合淨利潤約4500萬港元。從2024財年經審覈除稅後綜合淨利潤轉爲2025財年未經審覈除稅後綜合淨虧損,主要歸因於2024財年集團確認出售附屬公司產生的一次性收益約5740萬港元,而在2025財年並無此類收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.